The Journal of Urology
Volume 179, Issue 4 , Pages 1235-1242, April 2008

The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer

  • Donald J. Tindall

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Urology Research, Mayo Clinic, 200 1st St. Southwest, Rochester, Minnesota 55905 (telephone: 507-284-8553; FAX: 507-284-2384).
    • ,
  • Roger S. Rittmaster

Mayo Clinic, Rochester, Minnesota, and GlaxoSmithKline (RSR), Research Triangle Park, North Carolina

Received 9 May 2007 published online 18 February 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0022-5347(07)03074-1

doi:10.1016/j.juro.2007.11.033

Refers to erratum:

  • Inhibiting 5α-Reductase Isoenzymes for Prostate Cancer , 23 April 2008

    The Journal of Urology June 2008 (Vol. 179, Issue 6, Page 2490)

The Journal of Urology
Volume 179, Issue 4 , Pages 1235-1242, April 2008

Article Tools

* Image Usage & Resolution